Sanofi: positive data for hemophilia in NEJM

(CercleFinance.com) - Sanofi has announced that the New England Journal of Medicine (NEJM) has published Phase III data on its investigational drug efanesoctocog alpha once weekly, which illustrate its potential to transform the treatment of hemophilia A.


These data demonstrate that efanesoctocog alpha achieves normal or near-normal levels of factor VIII activity (greater than 40%) for the majority of the week at one dose per week, the healthcare group said.

Sanofi says that its efanesoctocog alpha is currently under accelerated review by the US Food and Drug Administration (FDA), whose decision is expected on 28 February.


Copyright (c) 2023 CercleFinance.com. All rights reserved.